Skip to main content

Table 3 Baseline patient characteristics for different dosages of LMWH

From: Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital

Variable

Major underdose (n = 223)

Mild underdose (n = 51)

Recommended dose (n = 34)

Excess dose (n = 4)

PValue

Age, y

62.1 ± 10.7

67.0 ± 11.3

68.6 ± 12.8

77.0 ± 17.5

<0.001

 ≥75 years, n (%)

24 (10.8)

19 (37.3)

19 (55.9)

3 (75)

<0.001

Female, n (%)

60 (26.9)

10 (19.6)

6 (17.6)

1 (25)

0.531

Weight (kg)

70.3 ± 9.2

58.2 ± 9.1

55.8 ± 8.8

71.5 ± 9.1

<0.001

BMI

24.7 ± 2.9

21.6 ± 2.6

21.0 ± 3.1

26.2 ± 3.1

<0.001

Diagnosis, n (%)

    

0.167

 STEMI

37 (16.6)

9 (17.6)

6 (17.6)

1 (25)

 

 UA/NSTEMI

126 (56.5)

34 (66.7)

21 (61.8)

2 (50)

 

 Atrial fibrillation

54 (24.2)

6 (11.8)

7 (20.6)

0

 

 DVT

6 (2.7)

2 (3.9)

0

1 (25)

 

Hypertension

134 (60.1)

34 (66.7)

23 (67.6)

3 (75)

0.668

Diabetes mellitus

53 (23.8)

7 (13.7)

9 (26.5)

0

0.267

Severe RI

0

0

3 (8.8)

4 (100)

<0.001

Creatinine, mg/dl

0.8 ± 0.2

0.8 ± 0.2

1.0 ± 0.3

2.5 ± 1.0

<0.001

Creatinine clearance, ml/min

90.6 ± 26.8

69.7 ± 16.4

61.3 ±22.6

24.9 ± 5.0

<0.001

Administration duration, d

4.1 ± 2.1

3.9 ± 1.8

4.0 ± 1.6

6.5 ± 5.6

0.128

Length of hospital stay, d

8.8 ± 5.7

9.4 ± 5.8

8.2 ± 4.6

14.8 ± 16.8

0.179

Major adverse vascular events, n (%)

6 (2.7)

1 (2.0)

1 (2.9)

2 (50)

<0.001

  1. Abbreviations: LMWH, Low molecular weight heparin; BMI, body mass index; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, Unstable angina/Non ST-segment elevation myocardial infarction; DVT, Deep vein thrombosis; RI, renal insufficient.